Prognostic impact of radiotherapy timing in WHO grade 2 and 3 meningiomas utilizing an integrated molecular-morphologic classification - PubMed
5 hours ago
- #Meningiomas
- #Molecular Classification
- #Radiotherapy
- Study evaluates the prognostic impact of radiotherapy timing in WHO grade 2 and 3 meningiomas using an integrated molecular-morphologic classification (IntS).
- Retrospective analysis of 55 patients with WHO grade 2 and 3 meningiomas treated with adjuvant radiotherapy.
- Molecular analyses using Illumina 450k and 850k EPIC arrays stratified patients into low, intermediate, and high-risk groups based on WHO grading, CNVs, and Methylation Families (MF).
- Local failure-free survival (LFFS) rates after 5 years were 0% for MF-malignant, 77% for MF-benign, and 58% for MF-intermediate meningiomas.
- Significant correlation observed between CNVs and LFFS in the adjuvant setting.
- IntS model showed distinct 5-year LFFS disparities across risk categories, highlighting the impact of combined morphological and molecular characteristics.
- Integration of DNA-methylation and CNV-profiles into IntS offers enhanced prognostic differentiation for meningioma patients.
- Study suggests IntS can guide optimal timing of adjuvant radiotherapy, leading to more tailored treatment strategies.